Ann: Change in substantial holding from HHL, page-78

SRX is still an effective secondary treatment but the gloss has gone off a little, fire sale prices at the moment, it is as usual on the ASX oversold.

Not good look for Australian biopharma. Too many scientists, not enough corporate governance. The idea of scientists running medical research companies is something from last century. That Australia has scientists running companies like SRX is clearly ridiculous.

BTW: If you were a scientist and were any good, you would have left Australia a long time ago. Other biopharma companies in Australia now need a Priest to issue the last rites, noone will invest in Australian biopharma, those dogs don't hunt no more.